/PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) (the "Company") today shared a business update as it focuses on strategically positioning the Company to...
Lannett (LCI) delivered earnings and revenue surprises of 17.07% and 10.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Q2 Business and Financial Highlights: Net Sales were $80.9 Million Gross Margin was 18%, Adjusted Gross Margin was 19% Net Sales, Gross Margin and Adjusted...
/PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and...
/PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday,...
/PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today provided an update on the clinical advancement and development of its biosimilar insulin aspart and...
/PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the...
Lannett (LCI) delivered earnings and revenue surprises of 8.70% and 10.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
/PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday,...
/PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the US Food and Drug Administration (FDA) to manufacture...